Replies to post #141578 on PharmaCyte Biotech Inc (PMCB)

[Will777]

--------- ----
“...there were 25% more deals worth over $1 billion up front. Many of them underscored the continued popularity of targeted oncology, immunology and rare-disease assets, as well as an increasing confidence in experimental therapy platform technologies using oligonucleotide, gene- or cell-therapy modalities.”

----------
Not sure why you included this. A billion would not help this POS. That's only .40 per share. Based on past history, if the shares pop to .41 (best case) you might get out with a long time investor might get out with a profit. However, that assumes there is a no more dilution and IND is approved; Neither will happen. I think the RS will hasten the BK. With fewer shares and higher price I think most volume will dry up.

[DragonBear]

PMCB’s CIAB technology and the positive shift-into the_dumpster

for such treatment presents an extraordinarily high value following FDA approval and upon up listing to NASDAQ

Neither will happen.

Nano cellular encapsulation treatments are currently and by far thee best option against tumors

There is no such thing as "nano" cellular encapsulation per PMCB. Nano encapsulation is where one encapsulates a cellular component or molecule. Current example are the mRNA vaccines - mRNA encapsulated by nano-lipids.

Neither is squirting in Ifosfamide, and having cellulose encapsulated cells activate it, can be defined as "nano encapsulation".

“...there were 25% more deals worth over $1 billion up front. Many of them underscored the continued popularity of targeted oncology, immunology and rare-disease assets, as well as an increasing confidence in experimental therapy platform technologies using oligonucleotide, gene- or cell-therapy modalities.”

Of which none are applicable to the PMCB 1990s antiquated CIABs. Encasing cells in a cellulose membrane, so that they can produce enzyme, to activate Ifosfamide, has nothing to do with targeted oncology, immunology, or gene-cell therapies. Nada. Nothing. Nyet.

The trendy and compatible focus on gene editing and the adaptive immune treatments are so far unable to handle the hostile environment of a cancerous tumor.

Yet, that is what is attracting the money in those "25% more deals".

The word "technology" is a laugh when applied to PMCB. And no one is going to buy the antiquated Kenny Wonder Treatment, featuring the chemo drug Ifosfamide, already been found to be ineffective in 2nd line pancreatic cancer patients.